Microbiome Research is reshaping colorectal cancer treatment

ESMO shared on LinkedIn:

“ESMOGI24: Since the development of Colorectal Cancer (CRC) is intertwined with the gut microbiome, lessons learned about the importance of its composition in immune checkpoint inhibitor therapy response could be crucial in tailoring cancer care.

Being able to identify the patients with poor gut microbiota composition provides clinicians with the opportunity to manipulate the microbiome and thereby potentially enhance their subsequent response to immunotherapy.

Read the ESMO Daily Reporter article to explore how advancing Microbiome Research is reshaping CRC treatment.”

Source: ESMO/LinkedIn